-
公开(公告)号：US11969445B2
公开(公告)日：2024-04-30
申请号：US18232980
申请日：2023-08-11
Applicant: Seed Health, Inc.
Inventor： Joseph E. Kovarik
IPC: A61K35/74 , A61K31/58 , A61K31/715 , A61K35/00 , A61K38/17
CPC classification number: A61K35/74 , A61K31/58 , A61K31/715 , A61K38/1709 , A61K38/1758 , A61K2035/11
Abstract: A method and system for modulating an individual's microbiome in a manner such that individuals who are overweight, obese and/or suffer from cardiometabolic diseases and/or inflammatory bowel diseases are able to reduce the incidence of chronic conditions and diseases associated therewith. Certain embodiments are directed to a method and bacterial formulations for reducing the likelihood of developing NAFLD and NASH.
-
2.发明公开
公开(公告)号：US20240024382A1
公开(公告)日：2024-01-25
申请号：US18234132
申请日：2023-08-15
Applicant: Seed Health, Inc.
Inventor： Sherri Simmons , Joseph E. Kovarik
IPC: A61K35/741 , C12N15/11 , C12N9/22 , C12N1/20 , C12N15/74 , A61K9/48 , A61K35/747 , A61K35/745
CPC classification number: A61K35/741 , C12N15/11 , C12N9/22 , C12N1/20 , C12N15/74 , A61K9/4808 , A61K35/747 , A61K35/745 , C12N2310/20 , C12N2800/80 , A61K2035/115
Abstract: The present invention is directed to beneficially directing the bidirectional communication that exists between the brain and the gut so as to influence brain physiology, psychological responses and ultimately behavior in a positive manner by regulating an individual's mood, psychological symptoms, such as anxiety and depression and stress-related changes in brain function, by modifying the gut microbiome of an individual. An various embodiments, an individual's microbiome is modified in a manner to reduce the likelihood of stress, to reduce or treat symptoms affecting mental health and to promote the mental health of the individual. In certain embodiments, administration to an individual of at least three different bacteria species are combined to modify an individual's microbiome, selected from the group of Lacticaseibacillus paracasei, Coprococcus, Roseburia, Bifidobacterium, L. casei and Faecalibacterium prausnitzii, to reduce adverse psychological and/or physiological responses attendant to psychological stress. Other embodiments reduce certain bacterial populations, such as Veillonella and Megasphaer, while in other embodiments, bacteria that produce hydrogen sulfide, methane and acetate are reduced to beneficially affect an individual's mental health.
-
公开(公告)号：US20240024378A1
公开(公告)日：2024-01-25
申请号：US18235686
申请日：2023-08-18
Applicant: Seed Health, Inc.
Inventor： Sheri Simmons , Tye Jensen , Joseph E. Kovarik
IPC: A61K35/74 , A61K31/715 , A61K31/58 , A61K38/17
CPC classification number: A61K35/74 , A61K31/715 , A61K31/58 , A61K38/1758 , A61K38/1709 , A61K2035/11
Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria, postbiotics, metabolites and other microbe components to foster the growth and maintenance of a healthy skin microbiome. One embodiment includes a topical application of Lactobacillus crispatus to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, postbiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne, through the production of tryptophan metabolites that act as AHR agonists.
-
公开(公告)号：US20240024154A1
公开(公告)日：2024-01-25
申请号：US18234544
申请日：2023-08-16
Applicant: SEED HEALTH, INC.
Inventor： Sheri Simmons , Tye Jensen , Joseph E. Kovarik
IPC: A61F5/56
CPC classification number: A61F5/566
Abstract: A method and system to address the adverse effects on an individual's oral microbiome with the objective of restoring gingival health caused by exposure to sodium lauryl sulfate. Certain embodiments of the present invention facilitate the growth of desired bacteria in a human's mouth to reduce the likelihood of dental caries, halitosis, canker sores, and other oral diseases. Probiotic bacterial, bioactive flavonoid, xylitol and zinc compound compositions, provide effective prevention and treatment options, especially while precluding the use of sodium lauryl sulfate so as to reduce adverse consequences it has on gingival health.
-
公开(公告)号：US11844720B2
公开(公告)日：2023-12-19
申请号：US18103768
申请日：2023-01-31
Applicant: SEED HEALTH, INC.
Inventor： Tye Jensen , Joseph E. Kovarik
IPC: A61F5/56
CPC classification number: A61F5/566
Abstract: A method to facilitate the growth of desired bacteria in a human's mouth to reduce the likelihood of dental caries and halitosis and other oral diseases, and for inhibiting oral biofilm formation, gingivitis, periodontitis and halitosis via the employment of one or more probiotic bacterial, bioactive flavonoid, and zinc compound compositions effective in providing prevention and treatment options.
-
公开(公告)号：US11839632B2
公开(公告)日：2023-12-12
申请号：US18178847
申请日：2023-03-28
Applicant: Seed Health, Inc.
Inventor： Tye Jensen , Joseph E. Kovarik
IPC: A61K35/74 , A61K31/715 , A61K31/58 , A61K38/17 , A61K35/00
CPC classification number: A61K35/74 , A61K31/58 , A61K31/715 , A61K38/1709 , A61K38/1758 , A61K2035/11
Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. Embodiments include methods for treating an individual suffering from acne vulgaris by topically administering a composition that includes live bacteria selected from the group consisting of L. reuteri, L. johnsonii, L. crispatus, C. acnes, and Nitrosomonas eutropha, that have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1(Cpf1) system to reduce the production of a virulence factor of the bacteria.
-
公开(公告)号：US11826388B2
公开(公告)日：2023-11-28
申请号：US18087545
申请日：2022-12-22
Applicant: SEED HEALTH, INC.
Inventor： Sheri Simmons , Shanthi Parkar , Erin A. Miller , Joseph E. Kovarik
IPC: A61K35/74 , A61K31/715 , A61K31/58 , A61K38/17 , A61K35/00
CPC classification number: A61K35/74 , A61K31/58 , A61K31/715 , A61K38/1709 , A61K38/1758 , A61K2035/11
Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. A topical application of Lactobacillus crispatus is employed to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne. The topical application of Lactobacillus crispatus to an individual's skin reduces inflammation through the production of tryptophan metabolites that act as AHR agonists.
-
公开(公告)号：US11642382B2
公开(公告)日：2023-05-09
申请号：US17848759
申请日：2022-06-24
Applicant: SEED HEALTH, INC.
Inventor： Joseph E. Kovarik
IPC: A61K35/74 , A61K31/715 , A61K31/58 , A61K38/17 , A61K35/00
CPC classification number: A61K35/74 , A61K31/58 , A61K31/715 , A61K38/1709 , A61K38/1758 , A61K2035/11
Abstract: A method for treating an individual suffering from bladder cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, dostarlimab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.
-
公开(公告)号：US20230040879A1
公开(公告)日：2023-02-09
申请号：US17893384
申请日：2022-08-23
Applicant: Seed Health, Inc.
Inventor： Joseph E. Kovarik
IPC: A61K35/74 , A61K31/715 , A61K31/58 , A61K38/17
Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individuals microbiome to reduce the likelihood of osteoporosis.
-
公开(公告)号：US20220331375A1
公开(公告)日：2022-10-20
申请号：US17848759
申请日：2022-06-24
Applicant: SEED HEALTH, INC.
Inventor： Joseph E. Kovarik
IPC: A61K35/74 , A61K31/715 , A61K31/58 , A61K38/17
Abstract: A method for treating an individual suffering from bladder cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, dostarlimab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.
